Drug Trial Radar · NCT05266105
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Actual
Start
Dec 10, 2021
Primary completion
Mar 2026
Study completion Mar 2026
Sponsor
- Lead sponsor
- Olema Oncology, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Mar 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, Phase 1b dose escalation and expansion study to determine the maximum tolerated dose (MTD) of OP-1250 in combination with palbociclib (Ibrance®️, Pfizer Inc.). Purpose of study is to evaluate the safety and pharmacokinetic (PK) profile, and estimate the preliminary anti-tumor activity of the combination in adult subjects with hormone receptor-positive (ER+ / HER2-) advanced or metastatic breast cancer (MBC).
Conditions
- Breast Cancer
Interventions
PalazestrantDrug
Complete Estrogen Receptor Antagonist
PalbociclibDrug
Palbociclib is an approved CDK 4/6 Inhibitor drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting ToxicitiesTime frame: From Cycle 1 Day 1 through C1 Day 28
- Characterization and Incidence in Adverse Events and Serious Adverse EventsTime frame: From initial inform consent date through 30 days post last dose
- Plasma levels of OP-1250 and PalbociclibTime frame: Up to 9 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
Waratah, New South Wales, Australia
Clinical Trial Site
Westmead, New South Wales, Australia
Clinical Trial Site
South Brisbane, Queensland, Australia
Clinical Trial Site
Southport, Queensland, Australia
Clinical Trial Site
Clayton, Victoria, Australia
Clinical Trial Site
Frankston, Victoria, Australia
Clinical Trial Site
Geelong, Victoria, Australia
Clinical Trial Site
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.